Following SMC collaboration with NICE on MTA TA878: casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19:
sotrovimab (Xevudy®) is accepted for restricted use within NHSScotland.
Indication under review: Treatment of symptomatic adults and adolescents (aged 12 years and over and weighing at least 40kg) with acute COVID-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID infection
SMC restriction: patients with increased risk for progression to severe COVID-19, as defined in section 5 of NICE final guidance, and nirmatrelvir and ritonavir is contraindicated or unsuitable.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Download detailed advice249KB (PDF)
Medicine details
- Medicine name:
- sotrovimab (Xevudy)
- SMC ID:
- SMC2555
- Indication:
Treatment of symptomatic adults and adolescents (aged 12 years and over and weighing at least 40kg) with acute COVID-19 infection who do require oxygen supplementation and who are at increased risk of progressing to severe COVID infection.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Infections
- Submission type
- Collaboration
- Status
- Restricted
- Date advice published
- 29 March 2023